269 filings
Page 2 of 14
8-K
fzl10m70ycnymyvafvg
10 May 23
Sonnet BioTherapeutics Provides Fiscal Year 2023 Second Quarter and Year-to-Date Business and Earnings Update
7:30am
8-K
d64kmflh
18 Apr 23
Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
5:00pm
8-K
tsino4ntwib
24 Mar 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
2yo0 6so10ef8t9ks6
10 Mar 23
Regulation FD Disclosure
4:24pm
8-K
at9lx7
13 Feb 23
Sonnet BioTherapeutics Provides Fiscal Year 2023 First Quarter Business and Earnings Update
8:00am
8-K
lsfi8sd8gky 0qwnc1
13 Feb 23
Sonnet BioTherapeutics Announces Pricing of $15.0 Million Underwritten Public Offering
6:05am
8-K
qnm5xy
19 Jan 23
Sonnet BioTherapeutics Announces Pharmacokinetic and Pharmacodynamic Data in a Phase 1 Dose-Escalation Trial of SON-1010
8:15am
8-K
odi3zo5 r4aie
9 Jan 23
Sonnet BioTherapeutics Announces a Collaboration with Roche for the Clinical Evaluation of SON-1010 with atezolizumab in Ovarian Cancer
8:15am
8-K
00kqayf
15 Dec 22
Sonnet BioTherapeutics Provides Fiscal Year 2022 Business and Financial Update
4:41pm
8-K
qsi9yozwebjjj6q
9 Nov 22
Other Events
5:04pm
8-K
jur4 b2i5l
2 Nov 22
Sonnet BioTherapeutics Announces Interim Data in Two Phase 1 Dose-Escalation Trials of SON-1010
8:05am
8-K
hpzqcm2seswlrq
1 Nov 22
Regulation FD Disclosure
4:30pm
8-K
lvx6yy2ufz1yi l9
31 Oct 22
Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates
8:00am
8-K
4oex36g
17 Oct 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
egnacltwn74 9v88
4 Oct 22
Other Events
8:05am
8-K
ytal4mjjx4c
29 Sep 22
Sonnet BioTherapeutics Appoints Ms. Lori McNeill to the Board of Directors and Formalizes the Company’s Business Advisory Committee
5:11pm
8-K
kqv4nslhhdsdvb4le9
21 Sep 22
Other Events
5:23pm
8-K
ln9 pa1bsv
19 Sep 22
Material Modifications to Rights of Security Holders
8:30am
8-K
6zags
16 Sep 22
Sonnet BioTherapeutics Announces 1-for-14 Reverse Stock Split
8:30am
8-K
jns3rtz 34
25 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:00pm